ORAMED PHARMACEUTICALS INC. 8-K

What Happened Oramed Pharmaceuticals Inc. filed an 8-K on January 7, 2026 announcing it received an $18.0 million payment from Scilex Holdings Inc., described as full satisfaction of obligations under their Option Agreement. The company’s Board approved a cash dividend of $0.25 per share to reward stockholders; the dividend will be paid on January 26, 2026 to holders of record as of January 16, 2026. The company said the dividend will be funded with surplus capital.

Key Details

• $18.0 million payment received from Scilex Holdings Inc., satisfying the Option Agreement.
• $0.25 per share cash dividend approved by the Board.
• Dividend totals approximately $10.5 million based on current shares outstanding.
• Record date: January 16, 2026; payment date: January 26, 2026.

Why It Matters This filing signals a near-term cash inflow ($18M) to Oramed and a board decision to return cash to shareholders (≈$10.5M). For investors, the items are concrete capital events: the Scilex payment resolves that contractual obligation, and the dividend provides an immediate cash return to shareholders of record. Net of the announced payout, the transaction implies roughly $7.5M of remaining proceeds before accounting for other company uses or obligations, which may affect short-term liquidity and capital allocation.